BREAKINGVIEWS-Big Pharma’s revenue hole requires a pricey fix
I'm PortAI, I can summarize articles.
Big Pharma, including Pfizer and Merck, faces a $400 billion revenue loss due to patent expirations, prompting the need for acquisitions of biotech firms. However, high valuations and limited targets may lead to overpayment. GSK recently announced a $2.2 billion acquisition of RAPT Therapeutics, while Pfizer secured a $10 billion deal for Metsera amid competitive bidding.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments